[go: up one dir, main page]

PE20201444A1 - Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido - Google Patents

Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido

Info

Publication number
PE20201444A1
PE20201444A1 PE2020000511A PE2020000511A PE20201444A1 PE 20201444 A1 PE20201444 A1 PE 20201444A1 PE 2020000511 A PE2020000511 A PE 2020000511A PE 2020000511 A PE2020000511 A PE 2020000511A PE 20201444 A1 PE20201444 A1 PE 20201444A1
Authority
PE
Peru
Prior art keywords
metoxy
pyrazol
benzaldehyde
pyridin
isopropyl
Prior art date
Application number
PE2020000511A
Other languages
English (en)
Inventor
Zhe Li
Travis Houston
Stephan D Parent
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53774359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20201444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of PE20201444A1 publication Critical patent/PE20201444A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA DE LA BASE LIBRE DE 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL-5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHIDO (COMPUESTO 1) CARACTERIZADO POR UN PATRON DE DIFRACCION DE RAYOS X EN POLVO (RADIACION Cu Kalfa) QUE TIENE PICOS DE DIFRACCION DE RAYOS X EN POLVO CON RADIACION Cu Kalfa A 13.37°, 14.37°, 19.95° Y 23.92° 2THETA (CADA UNO ±0.2 °2THETA). REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHA FORMA CRISTALINA ES UTIL PARA EL TRATAMIENTO DE LA ANEMIA DREPANOCITICA
PE2020000511A 2014-02-07 2015-02-05 Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido PE20201444A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937393P 2014-02-07 2014-02-07
US201461937404P 2014-02-07 2014-02-07
PCT/US2015/014589 WO2015120133A1 (en) 2014-02-07 2015-02-05 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Publications (1)

Publication Number Publication Date
PE20201444A1 true PE20201444A1 (es) 2020-12-10

Family

ID=53774359

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020000511A PE20201444A1 (es) 2014-02-07 2015-02-05 Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
PE2016000022A PE20160179A1 (es) 2014-02-07 2015-02-05 Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016000022A PE20160179A1 (es) 2014-02-07 2015-02-05 Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido

Country Status (31)

Country Link
US (7) US9447071B2 (es)
EP (2) EP3102208B2 (es)
JP (4) JP6809681B2 (es)
KR (2) KR102345380B1 (es)
CN (4) CN114213390A (es)
AP (1) AP2016009261A0 (es)
AU (3) AU2015214182B2 (es)
BR (1) BR112015032160B1 (es)
CA (1) CA2916564C (es)
CY (1) CY1124097T1 (es)
DK (1) DK3102208T4 (es)
EA (1) EA028529B1 (es)
ES (1) ES2860648T5 (es)
FI (1) FI3102208T4 (es)
HR (1) HRP20210388T4 (es)
HU (1) HUE053706T2 (es)
IL (2) IL243214B (es)
LT (1) LT3102208T (es)
MX (2) MX361810B (es)
MY (1) MY189995A (es)
PE (2) PE20201444A1 (es)
PL (1) PL3102208T5 (es)
PT (1) PT3102208T (es)
RS (1) RS61653B2 (es)
SA (1) SA516370358B1 (es)
SG (4) SG11201510135XA (es)
SI (1) SI3102208T2 (es)
SM (1) SMT202100160T1 (es)
TW (4) TWI755952B (es)
WO (1) WO2015120133A1 (es)
ZA (1) ZA202401707B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
PE20181519A1 (es) 2011-12-28 2018-09-21 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
BR112015021985B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6463327B2 (ja) 2013-03-15 2019-01-30 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
JP6809681B2 (ja) * 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (zh) * 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017218960A1 (en) 2016-06-17 2017-12-21 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
CN106227475A (zh) * 2016-07-18 2016-12-14 重庆市中迪医疗信息科技股份有限公司 打印系统及其方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
MA54231B1 (fr) 2018-11-19 2021-12-31 Global Blood Therapeutics Inc Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
WO2020127924A1 (en) * 2018-12-21 2020-06-25 Bionice, S.L.U. Process and intermediates for the preparation of voxelotor
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
EP3693364A1 (en) 2019-02-11 2020-08-12 Sandoz Ag Crystalline salts of a hemoglobin s allosteric modulator
WO2021046815A1 (zh) * 2019-09-12 2021-03-18 凯莱英医药化学（阜新）技术有限公司 一种连续化制备2,6-二羟基苯甲醛的装置及其应用
US20230015823A1 (en) 2019-11-19 2023-01-19 Global Blood Therapeutics, Inc. Methods of administering voxelotor
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
GB202002560D0 (en) * 2020-02-24 2020-04-08 Johnson Matthey Plc Crystalline forms of voxelotor, and processes for the preparation thereof
EP3888750A1 (en) 2020-04-02 2021-10-06 Sandoz AG Crystalline form of voxelotor
IT202000009970A1 (it) 2020-05-05 2021-11-05 Dipharma Francis Srl Procedimento per la preparazione di un farmaco per il trattamento dell’anemia falciforme
WO2021224280A1 (en) 2020-05-05 2021-11-11 Dipharma Francis S.R.L. Synthesis of a sickle cell disease agent and intermediates thereof
WO2022013052A1 (en) 2020-07-15 2022-01-20 Sandoz Ag Compounds comprising voxelotor and 2,5-dihydroxybenzoic acid and crystal forms
EP3939589A1 (en) 2020-07-15 2022-01-19 Sandoz Ag High drug load tablet comprising voxelotor
CN112047924B (zh) * 2020-10-10 2023-04-18 山东汇海医药化工有限公司 一种沃克洛多的制备方法
CA3200662A1 (en) 2020-11-06 2022-05-12 Global Blood Therapeutics, Inc. Process for preparation of 2-hydroxy-6-((2-(1-isopropyl- 1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN116710441A (zh) * 2020-11-06 2023-09-05 全球血液疗法公司 制备2-羟基-6-((2-(1-异丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)苯甲醛的方法
WO2022121670A1 (zh) * 2020-12-10 2022-06-16 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
WO2022177557A1 (en) * 2021-02-17 2022-08-25 Springworks Therapeutics, Inc. Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022249200A1 (en) * 2021-05-25 2022-12-01 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridine-3-yl) methoxy)benzaldehyde
IL312447A (en) 2021-11-05 2024-06-01 Global Blood Therapeutics Inc Methods of treating sickle cell disease with Oxbryta
WO2023199345A1 (en) * 2022-04-14 2023-10-19 Msn Laboratories Private Limited, R&D Center Novel solid state forms of voxelotor and their preparation methods thereof
CN115636742B (zh) * 2022-11-11 2024-04-09 江西亚太科技发展有限公司 一种重结晶的方法

Family Cites Families (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL214522A (es) 1956-02-13 1900-01-01
BE787580A (fr) 1971-08-13 1973-02-14 Hoechst Ag Procede de preparation de derives du furanne
BE787576A (fr) 1971-08-13 1973-02-14 Hoechst Ag Derives de benzofuranne et leur utilisation comme azureurs optiques
GB1409865A (en) 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
GB1593417A (en) 1976-12-22 1981-07-15 Squibb & Sons Inc Carbocyclic-fused pyrazolopyridine derivatives
US4062858A (en) 1976-12-22 1977-12-13 E. R. Squibb & Sons, Inc. Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines
DE2964427D1 (en) 1978-10-04 1983-02-03 Ciba Geigy Ag Process for the preparation of furanyl-benzazoles
DE2853765A1 (de) 1978-12-13 1980-06-26 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuranen
DE2904829A1 (de) 1979-02-08 1980-08-14 Bayer Ag Verfahren zur herstellung von benzimidazolylbenzofuran
IT1133025B (it) 1979-06-29 1986-07-09 Wellcome Found Nuovi eteri per uso farmaceutico e procedimento per la loro preparazione
IT1193786B (it) 1980-12-18 1988-08-24 Wellcome Found Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
JPS5929667A (ja) 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
US4478834A (en) 1983-02-11 1984-10-23 Usv Pharmaceutical Corporation Dihydropyridines and their use in the treatment of asthma
GB8402740D0 (en) 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
DE3431004A1 (de) 1984-08-23 1986-03-06 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung
DD226590A1 (de) 1984-09-07 1985-08-28 Univ Leipzig Mittel zur phagenhemmung in mikrobiellen produktionsprozessen
GB8603475D0 (en) 1986-02-12 1986-03-19 Glaxo Group Ltd Chemical compounds
DK111387A (da) 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
DD258226A1 (de) 1987-03-05 1988-07-13 Fahlberg List Veb Verfahren zur herstellung von aroxymethylchinoxalinen
JPH07121937B2 (ja) 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd ２−フエノキシピリミジン誘導体及び除草剤
GB8711802D0 (en) 1987-05-19 1987-06-24 Fujisawa Pharmaceutical Co Dithioacetal compounds
GB8718940D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
US4920131A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
JP2650038B2 (ja) 1988-01-27 1997-09-03 サントリー株式会社 ピロリチジン化合物およびその用途
JPH01305081A (ja) 1988-04-04 1989-12-08 E R Squibb & Sons Inc ３―アシルアミノ―１―［［［（置換スルホニル）アミノ〕カルボニル〕アミノ〕―２―アゼチジノン類
US4952574A (en) 1988-09-26 1990-08-28 Riker Laboratories, Inc. Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides
IE81170B1 (en) 1988-10-21 2000-05-31 Zeneca Ltd Pyridine derivatives
DD276480A1 (de) 1988-10-26 1990-02-28 Fahlberg List Veb Verfahren zur herstellung von naphtho/2,1-b/fur-2-ylchinoxalinen
DD276479A1 (de) 1988-10-26 1990-02-28 Fahlberg List Veb Verfahren zur herstellung von benzo/b/fur-2-ylchinoxalinen
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT1230859B (it) 1989-06-05 1991-11-08 Corvi Camillo Spa 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
AU641769B2 (en) 1990-06-18 1993-09-30 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
NZ238624A (en) 1990-06-19 1994-08-26 Meiji Seika Co Pyridine derivatives, compositions, preparations and use thereof
NL9001752A (nl) 1990-08-02 1992-03-02 Cedona Pharm Bv Nieuwe 1,4-dihydropyridinederivaten.
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5403816A (en) 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
JPH05301872A (ja) 1992-04-23 1993-11-16 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
WO1992013841A1 (de) 1991-02-08 1992-08-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Komplexbildner
JPH0641118A (ja) 1991-05-31 1994-02-15 Kumiai Chem Ind Co Ltd ピコリン酸誘導体及び除草剤
US5185251A (en) 1991-06-07 1993-02-09 Merck & Co., Inc. Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5202243A (en) 1991-10-04 1993-04-13 Merck & Co., Inc. Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices
GB9203798D0 (en) 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JPH07508527A (ja) 1992-07-01 1995-09-21 ビイク　グルデン　ロンベルク　ヒェーミッシェ　ファブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 錯体形成剤
US5290941A (en) 1992-10-14 1994-03-01 Merck & Co., Inc. Facile condensation of methylbenzoxazoles with aromatic aldehydes
US5521202A (en) 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
DE4318550A1 (de) 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5534529A (en) 1993-06-30 1996-07-09 Sankyo Company, Limited Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
JPH0725882A (ja) 1993-07-07 1995-01-27 Res Dev Corp Of Japan アクロメリン酸ｂおよびｅを製造するための中間体と、その製造方法
DK0637586T3 (da) 1993-08-05 1999-12-06 Hoechst Marion Roussel Inc 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
EP0640609A1 (en) 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
WO1995014015A1 (en) 1993-11-19 1995-05-26 Ciba-Geigy Ag Benzothiophene derivatives possessing a methoxyimino substituent as microbicides
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
EP0750631B1 (en) 1994-02-14 2000-04-05 Merrell Pharmaceuticals Inc. Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE4442050A1 (de) 1994-11-25 1996-05-30 Hoechst Ag Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien
US5650408A (en) 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
JP3895404B2 (ja) 1996-05-17 2007-03-22 興和株式会社 カルコン誘導体及びこれを含有する医薬
CN1221417A (zh) 1996-07-26 1999-06-30 雷迪博士研究基金会 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
AU717430B2 (en) 1996-08-26 2000-03-23 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO1998009967A1 (fr) 1996-09-09 1998-03-12 Kyowa Hakko Kogyo Co., Ltd. Derives de pyrrolocarbazole
CN1237166A (zh) 1996-11-12 1999-12-01 诺瓦提斯公司 可用作除草剂的吡唑衍生物
US6043389A (en) 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US5760232A (en) 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
KR100349385B1 (ko) 1997-12-12 2002-08-24 유로-셀티크 소시에떼 아노뉨 2-티오크산틴으로부터 얻어진 3-치환 아데닌
AU3297099A (en) 1998-02-25 1999-09-15 Genetics Institute Inc. Inhibitors of phospholipase a2
JP2002506873A (ja) 1998-03-18 2002-03-05 アリアド・ファーマシューティカルズ・インコーポレイテッド 複素環式シグナル伝達阻害剤、それを含む組成物
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9810860D0 (en) 1998-05-20 1998-07-22 Hoechst Schering Agrevo Gmbh Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
ATE274491T1 (de) 1998-12-14 2004-09-15 Hoffmann La Roche Phenylglycin-derivate
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
CA2358955A1 (en) 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
US6683213B1 (en) 1999-03-31 2004-01-27 Basf Aktiengesellschaft Substituted aniline compounds
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
WO2000069472A2 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
US6184228B1 (en) 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
WO2001000612A2 (en) 1999-06-28 2001-01-04 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
CN100334085C (zh) 1999-09-28 2007-08-29 卫材R&D管理有限公司 奎宁环化合物和包含该化合物作为活性成分的药物
CN1384814B (zh) 1999-11-05 2015-11-25 艾米斯菲尔技术有限公司 用于送递活性剂的苯氧基羧酸化合物和组合物
AUPQ407699A0 (en) 1999-11-16 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
ATE253561T1 (de) 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2001057044A1 (en) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
US6506755B2 (en) 2000-02-03 2003-01-14 Hoffmann-La Roche Inc. Thiazolidinecarboxyl acids
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
JP2003528068A (ja) 2000-03-17 2003-09-24 コリクサ コーポレイション 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
HU230316B1 (hu) 2000-07-14 2016-01-28 F. Hoffmann-La Roche Ag N-oxidok, mint 4-fenil-piridin-származékok előgyógyszerei, eljárás és előállításukra és az ezeket tartalmazó gyógyszerkészítmények
AU2001281071A1 (en) 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
US6653313B2 (en) 2000-08-10 2003-11-25 Warner-Lambert Company Llc 1,4-dihydropyridine compounds as bradykinin antagonists
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AUPR034000A0 (en) 2000-09-25 2000-10-19 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
CN1267424C (zh) 2000-11-20 2006-08-02 比奥维特罗姆股份公司 作为5－羟色胺5ht－2受体的激动剂或拮抗剂的哌嗪基吡嗪化合物
WO2002051849A1 (en) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
DE60139025D1 (de) 2000-12-28 2009-07-30 Takeda Pharmaceutical Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
GB0102595D0 (en) 2001-02-01 2001-03-21 Virk Kuldip Smart solar
US20030022923A1 (en) 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
MXPA04000695A (es) 2001-07-23 2005-08-26 Galileo Pharmaceuticals Inc Compuestos citoprotectores, formulaciones farmaceuticas y cosmeticas y metodos.
JP2003075970A (ja) 2001-08-31 2003-03-12 Konica Corp ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法
KR100467313B1 (ko) 2001-11-22 2005-01-24 한국전자통신연구원 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
RU2004121898A (ru) 2001-12-19 2006-01-20 Атеродженикс, Инк. (Us) Производные халкона и их применение для лечения заболеваний
US20030190333A1 (en) 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
EP1542704A1 (en) 2002-04-18 2005-06-22 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
US7368578B2 (en) 2002-09-10 2008-05-06 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
WO2004050030A2 (en) 2002-12-04 2004-06-17 Virginia Commonwealth University Anti-sickling agents
WO2004056727A2 (en) 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
CA2509835A1 (en) 2002-12-25 2004-07-15 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
DE50303264D1 (de) 2003-02-24 2006-06-08 Randolph Riemschneider Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung
US20040186077A1 (en) 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
RU2337908C2 (ru) 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
AU2004291262C1 (en) 2003-11-05 2011-08-11 F. Hoffmann-La Roche Ag Phenyl derivatives as PPAR agonists
CA2543913A1 (en) 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
CN101966183A (zh) 2003-12-02 2011-02-09 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
US7378439B2 (en) 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
WO2005074513A2 (en) 2004-01-30 2005-08-18 Merck & Co., Inc. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
AU2005221864A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
US20080132458A1 (en) 2004-03-10 2008-06-05 Threshold Pharmaceuticals, Inc. Hypoxia-Activated Anti-Cancer Agents
DE102004015226B3 (de) 2004-03-24 2005-08-25 Siemens Ag Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung
AU2005234796A1 (en) 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008517956A (ja) 2004-10-28 2008-05-29 メディキュア・インターナショナル・インコーポレーテッド 二重の抗血小板性／抗凝固性ピリドキシン類似体
JP2008523139A (ja) 2004-12-14 2008-07-03 アストラゼネカ・アクチエボラーグ 置換アミノピリジン類及びその使用
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
WO2006101318A1 (en) 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
GB0506677D0 (en) 2005-04-01 2005-05-11 Btg Int Ltd Iron modulators
BRPI0610030B8 (pt) 2005-04-28 2022-01-11 Glaxosmithkline Llc Composto, composição farmacêutica, e, uso de um composto
DE102005025989A1 (de) 2005-06-07 2007-01-11 Bayer Cropscience Ag Carboxamide
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
GB0516270D0 (en) 2005-08-08 2005-09-14 Glaxo Group Ltd Novel compounds
JP5557449B2 (ja) 2005-10-11 2014-07-23 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾフラン化合物
WO2007049675A1 (ja) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
JP2009515997A (ja) 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
WO2007084914A2 (en) 2006-01-17 2007-07-26 Neurocrine Biosciences, Inc. Phenoxy-substituted pyrimidines as adenosine receptor antagonists
WO2007095495A2 (en) 2006-02-13 2007-08-23 Pharmacopeia, Inc. Benzodiazepine gcnf modulators for stem cell modulation
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
GB0614586D0 (en) 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
CN101113148A (zh) 2006-07-26 2008-01-30 中国海洋大学 二氧哌嗪类化合物及其制备方法和用途
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
CN101506143B (zh) 2006-09-03 2013-06-05 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的对乙酰氨基酚及其相关化合物的前药
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
US8119681B2 (en) 2006-10-23 2012-02-21 Merck Sharp & Dohme Corp. 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands
TW200835687A (en) 2006-11-30 2008-09-01 R Tech Ueno Ltd Thiazole derivatives and their use as VAP-1 inhibitor
FR2909379B1 (fr) 2006-11-30 2009-01-16 Servier Lab Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2670984A1 (en) 2006-11-30 2008-06-05 Tokyo Institute Of Technology Novel curcumin derivative
CN103396359B (zh) 2007-02-22 2016-06-29 先正达参股股份有限公司 亚胺吡啶衍生物和它们作为杀微生物剂的用途
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
CN101679172B (zh) 2007-05-22 2013-05-29 住友化学株式会社 苯甲醛化合物的制造方法
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
ES2423181T3 (es) 2007-07-17 2013-09-18 F. Hoffmann-La Roche Ag Inhibidores de la 11ß-hidroxiesteroide-deshidrogenasa
JP5090528B2 (ja) 2007-07-26 2012-12-05 ノバルティス アーゲー ＡＬＫ４またはＡＬＫ５が介在する疾患を処置するための２、３、７位置換イミダゾ［１，２−ｂ］ピリダジン類
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
JP5456681B2 (ja) 2007-10-17 2014-04-02 ノバルティス アーゲー ＡＬＫ阻害剤として有用なイミダゾ［１，２−ａ］ピリジン誘導体
MX2010005717A (es) 2007-12-04 2010-06-02 Hoffmann La Roche Derivados de isoxazolo-piridina.
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP2009203230A (ja) 2008-01-31 2009-09-10 Daiichi Sankyo Co Ltd ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物
US8258349B2 (en) 2008-02-14 2012-09-04 Suitomo Chemical Company, Limited Process for production of benzaldehyde compound
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
RU2010145916A (ru) 2008-04-11 2012-05-20 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) Ингибитор pai-1
JP2011136906A (ja) 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
CA2723233C (en) 2008-05-08 2017-06-13 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
AU2009253812A1 (en) 2008-06-04 2009-12-10 Ambrilia Biopharma Inc. HIV integrase inhibitors from pyridoxine
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
JP5314330B2 (ja) 2008-06-16 2013-10-16 住友化学株式会社 ２−（アリールオキシメチル）ベンズアルデヒドの製造方法およびその中間体
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
JP2012508692A (ja) 2008-11-12 2012-04-12 シェーリング コーポレイション 脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
EP2732818B1 (en) 2009-03-31 2017-05-03 Ligand Pharmaceuticals Inc. A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis
US8367654B2 (en) 2009-05-08 2013-02-05 Tetraphase Pharmaceuticals, Inc. 8-AZA tetracycline compounds
WO2011024869A1 (ja) 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
US20120245344A1 (en) 2009-08-31 2012-09-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
EP2480533A1 (en) 2009-09-21 2012-08-01 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
DK2498756T4 (da) 2009-11-09 2023-03-20 Wyeth Llc Tabletformuleringer af neratinibmaleat
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
KR101698153B1 (ko) 2010-04-26 2017-01-23 광주과학기술원 Ｐ2ｘ1 및 ｐ2ｘ3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물
CN102232949A (zh) 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
TWI535442B (zh) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
CN103003283A (zh) * 2010-06-09 2013-03-27 Abbvie公司 激酶抑制剂的结晶形式
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
CN102116772B (zh) 2010-09-28 2013-08-28 上海大学 二氢查尔酮化合物的筛选方法
SG190905A1 (en) 2010-12-27 2013-07-31 Takeda Pharmaceutical Orally disintegrating tablet
WO2012138981A2 (en) 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
CA2832650C (en) 2011-04-11 2019-05-07 Pharma Eight Co. Ltd. Pyrazole derivative
CN102952062B (zh) 2011-08-12 2016-06-08 中国医学科学院医药生物技术研究所 取代苯并杂环类化合物及其制备方法和应用
CN105949193A (zh) * 2011-09-15 2016-09-21 德莫科斯公司 降伊波加因碱盐非溶剂化物
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
PE20181519A1 (es) 2011-12-28 2018-09-21 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2940012B1 (en) 2012-12-27 2019-01-30 Sumitomo Chemical Company Limited Tetrazolinone compound and applications thereof
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2970315B1 (en) 2013-03-15 2021-09-15 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6463327B2 (ja) 2013-03-15 2019-01-30 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
WO2014150261A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulaton of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
BR112015021985B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150256A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031284A1 (en) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
WO2015031285A1 (en) 2013-08-27 2015-03-05 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015116061A1 (en) 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
TWI544395B (zh) 2014-09-26 2016-08-01 義隆電子股份有限公司 單層電容式觸控面板之掃描方法及裝置
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
MA54231B1 (fr) 2018-11-19 2021-12-31 Global Blood Therapeutics Inc Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine

Also Published As

Publication number Publication date
AU2022203213B2 (en) 2024-05-09
DK3102208T4 (da) 2024-08-26
TWI714182B (zh) 2020-12-21
IL243214A0 (en) 2016-02-29
EP3102208A4 (en) 2017-06-14
MX361810B (es) 2018-12-14
TWI799115B (zh) 2023-04-11
HRP20210388T4 (hr) 2024-10-11
US20160346263A1 (en) 2016-12-01
IL243214B (en) 2021-09-30
SG11201510135XA (en) 2016-01-28
KR20160118204A (ko) 2016-10-11
CN114181194A (zh) 2022-03-15
US20150225366A1 (en) 2015-08-13
CN114181195A (zh) 2022-03-15
TWI670265B (zh) 2019-09-01
EP3102208B2 (en) 2024-07-17
HUE053706T2 (hu) 2021-07-28
JP2017505347A (ja) 2017-02-16
EP3102208A1 (en) 2016-12-14
EA201592212A8 (ru) 2016-07-29
SA516370358B1 (ar) 2017-12-21
KR20220002722A (ko) 2022-01-06
AU2022203213A1 (en) 2022-06-02
NZ715029A (en) 2021-07-30
JP7444957B2 (ja) 2024-03-06
JP2021113225A (ja) 2021-08-05
WO2015120133A1 (en) 2015-08-13
CA2916564A1 (en) 2015-08-13
JP6809681B2 (ja) 2021-01-06
LT3102208T (lt) 2021-05-10
TWI755952B (zh) 2022-02-21
PL3102208T5 (pl) 2024-10-14
SG10201911668VA (en) 2020-01-30
CY1124097T1 (el) 2022-05-27
EP3102208B1 (en) 2021-01-13
SG10201911662YA (en) 2020-02-27
PL3102208T3 (pl) 2021-07-19
US10722502B2 (en) 2020-07-28
RS61653B2 (sr) 2024-10-31
US9447071B2 (en) 2016-09-20
ES2860648T3 (es) 2021-10-05
JP2019137699A (ja) 2019-08-22
US20180289686A1 (en) 2018-10-11
SG10201804139VA (en) 2018-06-28
DK3102208T3 (da) 2021-03-08
JP2023016994A (ja) 2023-02-02
KR102588476B1 (ko) 2023-10-11
CN105431147A (zh) 2016-03-23
EA028529B1 (ru) 2017-11-30
SMT202100160T1 (it) 2021-05-07
HRP20210388T1 (hr) 2021-04-16
SI3102208T2 (sl) 2024-10-30
EP3868745A1 (en) 2021-08-25
US10137118B2 (en) 2018-11-27
TW201612171A (en) 2016-04-01
AU2015214182B2 (en) 2020-04-30
ZA202401707B (en) 2025-04-30
MX2015017614A (es) 2016-04-07
PE20160179A1 (es) 2016-05-20
KR102345380B1 (ko) 2021-12-29
IL285918A (en) 2021-10-31
AU2015214182A1 (en) 2016-01-21
PT3102208T (pt) 2021-04-05
EA201592212A1 (ru) 2016-05-31
MY189995A (en) 2022-03-22
US20250032471A1 (en) 2025-01-30
SI3102208T1 (sl) 2021-07-30
CA2916564C (en) 2023-02-28
AU2020207778B2 (en) 2022-02-17
US20210161876A1 (en) 2021-06-03
CN114213390A (zh) 2022-03-22
US11452720B2 (en) 2022-09-27
US20220395492A1 (en) 2022-12-15
AP2016009261A0 (en) 2016-06-30
MX2022007912A (es) 2022-07-21
TW202003489A (zh) 2020-01-16
US20190255031A1 (en) 2019-08-22
BR112015032160B1 (pt) 2021-11-30
ES2860648T5 (es) 2024-11-27
TW202134227A (zh) 2021-09-16
FI3102208T4 (fi) 2024-09-23
AU2020207778A1 (en) 2020-08-06
RS61653B1 (sr) 2021-04-29
TW202245761A (zh) 2022-12-01
BR112015032160A8 (pt) 2020-01-14
BR112015032160A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
PE20201444A1 (es) Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
CL2019001520A1 (es) Composición farmaceutica para prevenir o tratar cancer de hígado, que comprende un polimorfo hexaóxido de tetraarsénico cristalino.
BR112016014014A2 (pt) composição, método para a produção de um composto e método para o tratamento de um material
AR103444A1 (es) Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
BR112015021540A2 (pt) processos para a preparação de um agente indutor de apoptose
BR112017023663A2 (pt) síntese direta de cu-cha por meio de combinação de um complexo cu e tetraetilamônio e aplicações em catálise.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
BR112017003051A2 (pt) composto, método para produção de material magnético
GT201500247A (es) Imidazopiridazinas sustituidas
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EP2955175A4 (en) COMPOUND, MATERIAL FOR FORMING A LAYERED LITHOGRAPHY FILM, LITHOGRAPHY LAYERING FILM AND STRUCTURAL FORMING METHOD
PT3611171T (pt) Método para a síntese de eliglustato e dos seus compostos intermédios
CL2016001095A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
EA201490578A1 (ru) Полиморфная форма питавастатина кальция
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
EP3899990A4 (en) ATOMIC INTERFEROMETER
PL410329A1 (pl) Kompleksy rutenu, sposób ich wytwarzania oraz ich zastosowanie
EP2995307A4 (en) ORAL PHARMACEUTICAL COMPOSITION FOR INCREASING HYPOXIETHERANCE
AR082435A1 (es) Valsartan altamente cristalino